In clinical variable network-based analysis, we found that cancer patients with the elevated levels of NT-proBNP and Troponin-T had a worse survival (Fig 6), further supporting the potential roles of cardiac biomarkers involved in cancer survival. This evidence concerns the gene NPPB and cancer.